Article
Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now
31 May 2011
Abstract excerpt
Although sickle cell disease (SCD) has a variable clinical course, many patients develop end-organ complications that are associated with significant morbidity and early mortality. Myeloablative allogeneic HSCT (allo-HSCT) is curative but has been historically performed only in children younger than 16 years of age. Modest modifications in the conditioning regimen and supportive care have improved outcome such...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.